Alternative Protein Scaffolds for Molecular Imaging and Therapy

Molecular targeting has tremendous potential to enhance the specificity and sensitivity of diagnostics and the safety and potency of therapeutics, as well as to induce unique and precise biological responses. Effective targeting requires specific binding of appropriate affinity, conjugation of effectors (e.g., toxins, radioisotopes, or fusion proteins) as needed, stable maintenance of activity, and effective delivery physiologically. Ideally, solutions to these challenges will be efficiently implemented for a multitude of molecular targets unique to the relevant pathophysiology. Protein scaffolds, molecular frameworks amenable to local diversity to introduce specific binding while retaining favorable biophysical characteristics, offer an intriguing general solution. While antibodies and their derivatives offer viable options, a host of alternative topologies prove superior in stability, size, production, and/or conjugation. Validated scaffolds include the fibronectin domain, knottin, designed ankyrin repeat protein, anticalin, and affibody among others. These scaffolds have demonstrated efficacy in preclinical animal models and, in some cases, clinical trials in therapy or imaging. These translational developments will be reviewed here. The future is bright for both antibodies and their alternatives. Research should be undertaken to identify the most efficacious scaffold for each individual clinical indication and application.

[1]  J. Willmann,et al.  Pharmacokinetically Stabilized Cystine Knot Peptides That Bind Alpha-v-Beta-6 Integrin with Single-Digit Nanomolar Affinities for Detection of Pancreatic Cancer , 2011, Clinical Cancer Research.

[2]  S. Gambhir,et al.  A 2-Helix Small Protein Labeled with 68Ga for PET Imaging of HER2 Expression , 2009, Journal of Nuclear Medicine.

[3]  Andreas Plückthun,et al.  A designed ankyrin repeat protein evolved to picomolar affinity to Her2. , 2007, Journal of molecular biology.

[4]  C. Ballantyne,et al.  Pharmacological strategies for lowering LDL cholesterol: statins and beyond , 2011, Nature Reviews Cardiology.

[5]  A. Koide,et al.  Stabilization of a fibronectin type III domain by the removal of unfavorable electrostatic interactions on the protein surface. , 2001, Biochemistry.

[6]  G. Paesen,et al.  Complement Inhibitor of C5 Activation from the Soft Tick Ornithodoros moubata , 2005, The Journal of Immunology.

[7]  A. Plückthun,et al.  DARPin-targeting of measles virus: unique bispecificity, effective oncolysis, and enhanced safety. , 2013, Molecular therapy : the journal of the American Society of Gene Therapy.

[8]  M. Mrugala,et al.  Outside the Box—Novel Therapeutic Strategies for Glioblastoma , 2012, Cancer journal.

[9]  S. Gambhir,et al.  An engineered knottin peptide labeled with 18F for PET imaging of integrin expression. , 2009, Bioconjugate chemistry.

[10]  M. Gonda,et al.  Phase I single-dose study of intracavitary-administered iodine-131-TM-601 in adults with recurrent high-grade glioma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  A. Koide,et al.  Exploring the potential of the monobody scaffold: effects of loop elongation on the stability of a fibronectin type III domain. , 2002, Protein engineering.

[12]  Martin C. Wright,et al.  Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2 , 2010, mAbs.

[13]  K. Wittrup,et al.  The full amino acid repertoire is superior to serine/tyrosine for selection of high affinity immunoglobulin G binders from the fibronectin scaffold. , 2010, Protein engineering, design & selection : PEDS.

[14]  R. Kimura,et al.  Engineered cystine knot peptides that bind αvβ3, αvβ5, and α5β1 integrins with low‐nanomolar affinity , 2009, Proteins.

[15]  A. Skerra,et al.  High-affinity recognition of lanthanide(III) chelate complexes by a reprogrammed human lipocalin 2. , 2009, Journal of the American Chemical Society.

[16]  Fredrik Y Frejd,et al.  Combining phage and staphylococcal surface display for generation of ErbB3-specific Affibody molecules. , 2011, Protein engineering, design & selection : PEDS.

[17]  Michael M. Schmidt,et al.  A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.

[18]  Jennifer L. Lahti,et al.  Engineered cystine-knot peptides that bind alpha(v)beta(3) integrin with antibody-like affinities. , 2009, Journal of molecular biology.

[19]  Michaela Gebauer,et al.  Engineered protein scaffolds as next-generation antibody therapeutics. , 2009, Current opinion in chemical biology.

[20]  Adam P. Silverman,et al.  Evaluation of a 64Cu-Labeled Cystine-Knot Peptide Based on Agouti-Related Protein for PET of Tumors Expressing αvβ3 Integrin , 2010, Journal of Nuclear Medicine.

[21]  R. Kimura,et al.  Functional Mutation of Multiple Solvent-Exposed Loops in the Ecballium elaterium Trypsin Inhibitor-II Cystine Knot Miniprotein , 2011, PloS one.

[22]  A. Plückthun,et al.  A Novel Fusion Toxin Derived from an EpCAM-Specific Designed Ankyrin Repeat Protein Has Potent Antitumor Activity , 2010, Clinical Cancer Research.

[23]  S. Ståhl,et al.  Non-immunoglobulin based protein scaffolds. , 2011, Current opinion in biotechnology.

[24]  R. Kimura,et al.  Preliminary evaluation of 177Lu-labeled knottin peptides for integrin receptor-targeted radionuclide therapy , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[25]  E. Souied,et al.  Phase I Mp0112 Wet AMD Study: Results Of A Single Escalating Dose Study With DARPin® MP0112 In Wet AMD , 2011 .

[26]  S. Gambhir,et al.  Engineered Two‐Helix Small Proteins for Molecular Recognition , 2009, Chembiochem : a European journal of chemical biology.

[27]  H. Lundqvist,et al.  Biodistribution of 211At labeled HER-2 binding affibody molecules in mice. , 2007, Oncology reports.

[28]  P. Nygren,et al.  Alternative binding proteins: Affibody binding proteins developed from a small three‐helix bundle scaffold , 2008, The FEBS journal.

[29]  Andreas Plückthun,et al.  Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. , 2010, Cancer research.

[30]  V. Prasad,et al.  Molecular Imaging of HER2-Expressing Malignant Tumors in Breast Cancer Patients Using Synthetic 111In- or 68Ga-Labeled Affibody Molecules , 2010, Journal of Nuclear Medicine.

[31]  J. Peterson,et al.  Adnectin CT-322 inhibits tumor growth and affects microvascular architecture and function in Colo205 tumor xenografts. , 2010, International journal of oncology.

[32]  V. Tolmachev,et al.  Radionuclide molecular imaging using Affibody molecules. , 2010, Current pharmaceutical biotechnology.

[33]  Christin Müller,et al.  Intravenous application of an anticalin dramatically lowers plasma digoxin levels and reduces its toxic effects in rats. , 2012, Toxicology and applied pharmacology.

[34]  H. Moch,et al.  Designed ankyrin repeat proteins: a novel tool for testing epidermal growth factor receptor 2 expression in breast cancer , 2010, Modern Pathology.

[35]  A. Lehmann Ecallantide (DX-88), a plasma kallikrein inhibitor for the treatment of hereditary angioedema and the prevention of blood loss in on-pump cardiothoracic surgery , 2008 .

[36]  Christopher M Pirie,et al.  Convergent Potency of Internalized Gelonin Immunotoxins across Varied Cell Lines, Antigens, and Targeting Moieties* , 2010, The Journal of Biological Chemistry.

[37]  A. Wentzel,et al.  The potential of cystine-knot microproteins as novel pharmacophoric scaffolds in oral peptide drug delivery , 2006, Journal of drug targeting.

[38]  Donghoon Lee,et al.  In vivo MRI detection of gliomas by chlorotoxin-conjugated superparamagnetic nanoprobes. , 2008, Small.

[39]  Jakob Dogan,et al.  Biophysical characterization of ZSPA‐1—A phage‐display selected binder to protein A , 2004, Protein science : a publication of the Protein Society.

[40]  M. Hassan,et al.  HER2-Affitoxin: A Potent Therapeutic Agent for the Treatment of HER2-Overexpressing Tumors , 2011, Clinical Cancer Research.

[41]  Justin K Scheer,et al.  CT322, a VEGFR-2 antagonist, demonstrates anti-glioma efficacy in orthotopic brain tumor model as a single agent or in combination with temozolomide and radiation therapy , 2012, Journal of Neuro-Oncology.

[42]  S. Gambhir,et al.  Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. , 2009, Cancer research.

[43]  Fredrik Y Frejd,et al.  Affibody molecules: Engineered proteins for therapeutic, diagnostic and biotechnological applications , 2010, FEBS letters.

[44]  A. D. Rodrigues,et al.  Development of a Carbon-14 Labeling Approach to Support Disposition Studies with a Pegylated Biologic , 2012, Drug Metabolism and Disposition.

[45]  T. Wurch,et al.  Novel protein scaffolds as emerging therapeutic proteins: from discovery to clinical proof-of-concept. , 2012, Trends in biotechnology.

[46]  J. Wolchok,et al.  Antibody therapy of cancer , 2012, Nature Reviews Cancer.

[47]  Zhen Cheng,et al.  Protein scaffold-based molecular probes for cancer molecular imaging , 2011, Amino Acids.

[48]  Jean-Christophe Gelly,et al.  KNOTTIN: the knottin or inhibitor cystine knot scaffold in 2007 , 2007, Nucleic Acids Res..

[49]  S. Gambhir,et al.  Cancer esearch rated Systems and Technologies Imaging of Tumor Neovascularization in a Transgenic R se Model with a Novel 64 Cu-DOTA-Knottin Peptide , 2010 .

[50]  S. Gambhir,et al.  Designed hydrophilic and charge mutations of the fibronectin domain: towards tailored protein biodistribution. , 2012, Protein engineering, design & selection : PEDS.

[51]  Zhen Cheng,et al.  Affibody modified and radiolabeled gold-iron oxide hetero-nanostructures for tumor PET, optical and MR imaging. , 2013, Biomaterials.

[52]  J. Mazières,et al.  A randomized, double-blinded, phase II study of paclitaxel/carboplatin (PC) plus CT-322 versus PC plus bevacizumab (Bev) as first-line treatment for advanced nonsquamous non-small cell lung cancer (NSCLC). , 2012 .

[53]  Gongping Yang,et al.  Finger Vein Recognition Based on (2D)2 PCA and Metric Learning , 2012, Journal of biomedicine & biotechnology.

[54]  S. Ståhl,et al.  Affinity proteins and their generation , 2013 .

[55]  Moritz A. Konerding,et al.  Anti-VEGFR2 and anti-IGF-1R-Adnectins inhibit Ewing’s sarcoma A673-xenograft growth and normalize tumor vascular architecture , 2012, Angiogenesis.

[56]  K. Wittrup,et al.  Stability and CDR composition biases enrich binder functionality landscapes. , 2010, Journal of molecular biology.

[57]  S. Gambhir,et al.  A novel 18F-labeled two-helix scaffold protein for PET imaging of HER2-positive tumor , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[58]  D. Neri,et al.  Tumor-targeting antibody-anticalin fusion proteins for in vivo pretargeting applications. , 2013, Bioconjugate chemistry.

[59]  Sanjiv S. Gambhir,et al.  Targeted Contrast-Enhanced Ultrasound Imaging of Tumor Angiogenesis with Contrast Microbubbles Conjugated to Integrin-Binding Knottin Peptides , 2010, Journal of Nuclear Medicine.

[60]  Sanjiv S Gambhir,et al.  18F-Fluorobenzoate–Labeled Cystine Knot Peptides for PET Imaging of Integrin αvβ6 , 2013, The Journal of Nuclear Medicine.

[61]  A. Plückthun,et al.  Engineering novel binding proteins from nonimmunoglobulin domains , 2005, Nature Biotechnology.

[62]  W. Stemmer,et al.  Multivalent avimer proteins evolved by exon shuffling of a family of human receptor domains , 2005, Nature biotechnology.

[63]  J. Andersen,et al.  Extending Half-life by Indirect Targeting of the Neonatal Fc Receptor (FcRn) Using a Minimal Albumin Binding Domain* , 2010, The Journal of Biological Chemistry.

[64]  Arne Skerra,et al.  Lipocalins in drug discovery: from natural ligand-binding proteins to "anticalins". , 2005, Drug discovery today.

[65]  A. Plückthun,et al.  DARPins: an efficient targeting domain for lentiviral vectors. , 2011, Molecular therapy : the journal of the American Society of Gene Therapy.

[66]  B. Gong,et al.  Novel complement inhibitor limits severity of experimentally myasthenia gravis , 2009, Annals of neurology.

[67]  Martin C. Wright,et al.  A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor , 2011, mAbs.

[68]  Nina M. Muñoz,et al.  Tumor paint: a chlorotoxin:Cy5.5 bioconjugate for intraoperative visualization of cancer foci. , 2007, Cancer research.

[69]  S. Ståhl,et al.  Re-targeted adenovirus vectors with dual specificity; binding specificities conferred by two different Affibody molecules in the fiber , 2009, Gene Therapy.

[70]  J. Cochran,et al.  Engineering knottins as novel binding agents. , 2012, Methods in enzymology.

[71]  Y. Chen,et al.  Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two. , 2005, Protein engineering, design & selection : PEDS.

[72]  Lin Sun,et al.  Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro. , 2006, Chemistry & biology.

[73]  M. Joppa,et al.  Central infusion of the melanocortin receptor antagonist agouti-related peptide (AgRP(83-132)) prevents cachexia-related symptoms induced by radiation and colon-26 tumors in mice , 2007, Peptides.

[74]  Michelle L Colgrave,et al.  Thermal, chemical, and enzymatic stability of the cyclotide kalata B1: the importance of the cyclic cystine knot. , 2004, Biochemistry.

[75]  G. Steinberg,et al.  SNX-111, a novel, presynaptic N-type calcium channel antagonist, is neuroprotective against focal cerebral ischemia in rabbits , 1997, Journal of the Neurological Sciences.

[76]  A. Mamelak,et al.  Imaging glioma extent with 131I-TM-601. , 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[77]  S. Gambhir,et al.  A dual-labeled knottin peptide for PET and near-infrared fluorescence imaging of integrin expression in living subjects. , 2010, Bioconjugate chemistry.

[78]  A. A. Knecht EVALUATION OF A , 1972 .

[79]  J. Cochran,et al.  Knottins: disulfide-bonded therapeutic and diagnostic peptides. , 2012, Drug discovery today. Technologies.

[80]  P. Campochiaro,et al.  Treatment of diabetic macular edema with a designed ankyrin repeat protein that binds vascular endothelial growth factor: a phase I/II study. , 2013, American journal of ophthalmology.

[81]  Manuel Simon,et al.  Designed ankyrin repeat proteins (DARPins) from research to therapy. , 2012, Methods in enzymology.

[82]  Laura A. Sullivan,et al.  The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer , 2008, BMC Cancer.

[83]  P. Kaye,et al.  An engineered lipocalin specific for CTLA-4 reveals a combining site with structural and conformational features similar to antibodies , 2009, Proceedings of the National Academy of Sciences.

[84]  H. Willison,et al.  C5 inhibitor rEV576 protects against neural injury in an in vitro mouse model of Miller Fisher syndrome , 2008, Journal of the peripheral nervous system : JPNS.

[85]  Joachim Feldwisch,et al.  Design of an optimized scaffold for affibody molecules. , 2010, Journal of molecular biology.

[86]  Laurent Chiche,et al.  New binding specificities derived from Min-23, a small cystine-stabilized peptidic scaffold. , 2005, Biochemistry.

[87]  Fredrik Y Frejd,et al.  Engineered high-affinity affibody molecules targeting platelet-derived growth factor receptor β in vivo. , 2011, Journal of molecular biology.

[88]  Adam P. Silverman,et al.  111In-Labeled Cystine-Knot Peptides Based on the Agouti-Related Protein for Targeting Tumor Angiogenesis , 2012, Journal of biomedicine & biotechnology.

[89]  E. Lundberg,et al.  Selection and characterization of Affibody® ligands to the transcription factor c‐Jun , 2009, Biotechnology and applied biochemistry.

[90]  K.,et al.  Triepitopic antibody fusions inhibit cetuximab-resistant BRAF and KRAS mutant tumors via EGFR signal repression. , 2012, Journal of molecular biology.

[91]  A. Tolcher,et al.  Phase I and Pharmacokinetic Study of CT-322 (BMS-844203), a Targeted Adnectin Inhibitor of VEGFR-2 Based on a Domain of Human Fibronectin , 2011, Clinical Cancer Research.

[92]  Sanjiv S Gambhir,et al.  Use of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging. , 2012, Radiology.

[93]  A. Kapila,et al.  Picomolar affinity fibronectin domains engineered utilizing loop length diversity, recursive mutagenesis, and loop shuffling. , 2008, Journal of molecular biology.

[94]  Michaela Gebauer,et al.  Anticalins small engineered binding proteins based on the lipocalin scaffold. , 2012, Methods in enzymology.

[95]  A novel radiofluorinated agouti-related protein for tumor angiogenesis imaging , 2013, Amino Acids.

[96]  B. Ryffel,et al.  Arthropod-Derived Histamine-Binding Protein Prevents Murine Allergic Asthma , 2004, The Journal of Immunology.

[97]  M. Ballmaier,et al.  Grafting of thrombopoietin‐mimetic peptides into cystine knot miniproteins yields high‐affinity thrombopoietin antagonists and agonists , 2006, The FEBS journal.

[98]  R K Jain,et al.  Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.